surmount-1 trial tirzepatide non-diabetic obesity weight loss Tirzepatide's Surmount-4 Reveals Groundbreaking Results Tirzepatide for the treatment of

FDA-approved for treating B12 deficiency

All authors contributed to the review and are responsible for the article content

This once-weekly injection is formulated for individuals with a BMI of 30 or more, or 27 or above with a weight-related condition

Does Zepbound Cause Headaches

Mechanism of Action: Why Two Receptors May Matter More Tirzepatide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIPR) receptors

Severe or persistent diarrhea defined as more than six loose stools daily lasting beyond 48 hoursrequires clinical assessment to prevent complications and rule out alternative causes unrelated to the weight loss medication